skip to navigation skip to content
Search

drug development

How can health care be delivered at lower cost?

Conference at Cambridge Judge Business School explores the development of Health Care Utilities that scale up innovations to reduce the cost of medicines and other health care products.  Professor Stefan Scholtes Life expectancy in the most advanced countries has increased…

Read more

A young pharmacist assists a customer.

From Breakthrough to Blockbuster

New book co-authored by Nektarios Oraiopoulos of Cambridge Judge Business School charts the rise of entrepreneurial biotech firms. Dr Nektarios Oraiopoulos From Breakthrough to Blockbuster: The Business of Biotechnology, published today, shows how the small, inexperienced entrepreneurial companies making up…

Read more

Small, inexperienced entrepreneurial companies making up the biotech industry have created more life-changing medicines than all of the large pharmaceutical companies combined.

Business Weekly: Qureight secures £1.5m to enhance AI solution in battle against complex diseases

Cambridge-based Qureight, a clinical data curation and analytics company, has raised £1.5 million seed funding to develop AI-powered platform allowing to collect data from complex diseases. “Qureight’s platform technology will allow biopharma companies to recruit fewer patients for clinical trials…

Read more

Carryover co-operation

Sir Mene Pangalos of AstraZeneca, in a Cambridge Judge interview, urges continuation of the 'exceptional' collaboration between industry, academia, government and regulators that led to rapid development of COVID-19 vaccines. Sir Mene Pangalos The "exceptional" collaboration between the pharmaceutical industry,…

Read more

Female scientist looking at ampoule with new medication, vaccination development.

Forbes India: How drug companies can increase their R&D effectiveness

A study co-authored by Professor Stylianos Kavadias and Dr Nektarios Oraiopoulos at University of Cambridge Judge Business School, is featured in the Forbes article. The study demonstrates “how pharmaceutical executives can impact the success of their research and development” programs…

Read more

Pharma shift

The pharmaceutical industry's focus on procedures and dealmaking could change significantly in this uncertain period, five Cambridge Executive MBA graduates say in a webinar for the What's Next? How to Survive and Thrive in a Post COVID-19 World series. Here's…

Read more

2020 webinars whats next 883x432 1

Investing in Cambridge drug discovery

PharmEnable raises £1.8 million for drug discovery expansion. PharmEnable, a venture supported by the Accelerate Cambridge programme at the Entrepreneurship Centre of Cambridge Judge Business School, said it has secured £1.8 million in a seed financing round led by Cambridge…

Read more

2020 news accelerate pharmenable 883x432 1

Biotech vs big pharma

Most approved "priority" medicines are developed by biotech rather than large pharmaceutical firms, says a two-decade study at the University of Cambridge Judge Business School. Biotech companies created 40 per cent more US Food & Drug Administration-approved "priority" drugs than…

Read more

2020 brainfood oraiopoulos derisking drug innovation 1998x642 1

Manhattan Project?

A "multiple-shots-on-goal" approach is needed to find coronavirus drugs, Cambridge Judge academics say in California Management Review. A many-shots-on-goal approach - not command and control - will most effectively develop vaccines and treatments for COVID-19 (coronavirus), Cambridge Judge Business School academics say in a new California Management Review article. Professor Christoph Loch While some have suggested…

Read more

2020 brainfood manhattan project 883x432 1

Drug trials

An Executive MBA alumnus, Dr Rav Seeruthun, heads a Roche team that has developed a drug being tested to fight COVID-19.  Dr Rav Seeruthun (EMBA 2013) of Cambridge Judge Business School, is heading a team at the Roche UK Medical Directorate that has developed…

Read more

2020 news drug trials 883x432 1

Archives